...
机译:BGJ398,成纤维细胞生长因子受体1-3抑制剂的功效,以先前治疗的先进尿路上皮癌,FGFR3改变
City Hope Natl Med Ctr Duarte CA USA;
Mem Sloan Kettering Canc Ctr 1275 York Ave New York NY 10065 USA;
Thomas Jefferson Univ Sidney Kimmel Canc Ctr Philadelphia PA 19107 USA;
Chaim Sheba Med Ctr Ramat Gan Israel;
USC Norris Canc Ctr Los Angeles CA USA;
Mt Sinai Hosp New York NY 10029 USA;
Univ Hosp Cologne Ctr Integrated Oncol Cologne Germany;
Kaiser Franz Josef Spital ACR ITR VIEnna Appl Canc Res Inst Translat Res Vienna Vienna Austria;
Seoul Natl Univ Hosp Seoul South Korea;
IUCT Oncopole Toulouse France;
Netherlands Canc Inst Amsterdam Netherlands;
Inst Paoli Calmettes Marseilles France;
Hop Europeen Georges Pompidou Paris France;
Hosp Santa Creu &
Sant Pau Barcelona Spain;
Chulalongkorn Univ Fac Med Bangkok Thailand;
Maharaj Nakorn Chiangmai Hosp Chiang Mai Thailand;
Sarah Cannon Res Inst Nashville TN USA;
Clin Hematol Hemostasis Oncol &
Stem Cell Transp Med Sch Hannover Hannover Germany;
Yale Sch Med New Haven CT USA;
Wayne State Univ Karmanos Canc Inst Detroit MI USA;
Tel Aviv Sourasky Med Ctr Ichilov Tel Aviv Israel;
Inst Sci Romagnolo Studio &
Cura Tumori IRST IRC Meldola Italy;
Univ Ulsan Asan Med Ctr Coll Med Seoul South Korea;
Vrije Univ Amsterdam Med Ctr Canc Ctr Amsterdam Amsterdam Netherlands;
Univ Utah Huntsman Canc Inst Salt Lake City UT USA;
Univ Utah Huntsman Canc Inst Salt Lake City UT USA;
Ohio State Univ Ctr Comprehens Canc Columbus OH 43210 USA;
Univ Penn Abramson Canc Ctr Philadelphia PA 19104 USA;
Novartis Pharmaceut E Hanover NJ USA;
Novartis Pharmaceut E Hanover NJ USA;
Novartis Pharmaceut E Hanover NJ USA;
Novartis Inst BioMed Res Cambridge MA USA;
Novartis Inst BioMed Res Cambridge MA USA;
Novartis Pharma AG Basel Switzerland;
Mem Sloan Kettering Canc Ctr 1275 York Ave New York NY 10065 USA;
机译:BGJ398,成纤维细胞生长因子受体1-3抑制剂的功效,以先前治疗的先进尿路上皮癌,FGFR3改变
机译:评价BGJ398,一种成纤维细胞生长因子受体1-3激酶抑制剂,患有成纤维细胞生长因子受体的遗传改变的患者:全球阶段I,剂量升级和剂量扩展研究的结果(Vol 35,PG 157,2017)
机译:鉴定使用RNA的测定在转移或局部晚期,手术不可切除的尿路上皮癌患者中使用RNA的测定,核癌癌的成纤维细胞生长因子受体遗传改变
机译:成纤维细胞生长因子-2与分离的完整细胞表面受体结合的计算模型:成纤维细胞生长因子-2浓度,流量和递送模式的影响
机译:表皮生长因子受体酪氨酸激酶抑制剂治疗晚期非小细胞肺癌疗效的预测生物标志物:随机对照试验的系统评价。
机译:BGJ398(一种成纤维细胞生长因子受体1-3抑制剂)在先前治疗的具有FGFR3改变的晚期尿路上皮癌患者中的疗效
机译:教师意见建议BGJ398,成纤维细胞生长因子受体1-3抑制剂在先前治疗的先进尿路上皮癌的患者中推荐疗效,具有FGFR3改变。